Pain relief trial for people with IBD and joint pain
Part of Digestive system clinical trials.
This study tests a treatment called GenesiDol for managing muscle and bone pain in people with inflammatory bowel disease (IBD). You may be able to join if you have ongoing pain without active joint swelling or inflammation.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have been diagnosed with IBD for at least 6 months.
- You have ongoing muscle or bone pain, but no active joint inflammation.
- You are not on blood thinning or seizure medications.
- You do not have other major health issues like diabetes or substance use disorder.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether brain training (neurofeedback) can help people with inflammatory bowel disease (IBD) manage ongoing muscle or joint pain that isn't caused by active inflammation.
This study looks at bacteria in your gut that may produce chemicals linked to ongoing pain in Crohn's disease or ulcerative colitis, even when the disease itself is not very active. Researchers want to understand why some people still have moderate to severe abdominal pain even after their inflammation has calmed down.
This trial tests whether guselkumab, a newer biologic medication, can treat people who have both inflammatory bowel disease (Crohn's disease or ulcerative colitis) and spondyloarthritis (joint inflammation and pain). Researchers want to see if this one drug can help both conditions at the same time.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
This trial tests a structured IBD (inflammatory bowel disease) management program that includes incentives to help people follow care plans. It aims to improve patients’ quality of life by supporting ongoing education and follow-up.
This trial is testing a new drug (a JAK inhibitor) for people with rare inflammatory diseases like Behçet's, myositis, or IgG4-related disease that hasn't improved with standard treatments. The goal is to see if it can help control symptoms and reduce inflammation.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.